Balyasny Asset Management
KPTI icon

Balyasny Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

Balyasny Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$557K Buy
+100,000
New +$762K ﹤0.01% 2324

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Balyasny Asset Management's KPTI Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in Karyopharm Therapeutics (KPTI) in Q1 2026: 70,748 shares worth $394K. The stake represents ﹤0.01% of the portfolio and ranks #2459 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in KPTI as recently as Q2 2024.

Balyasny Asset Management first reported a position in KPTI in Q3 2014 and has held it in 16 quarters since. The position peaked at $5.61M in Q4 2020. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Balyasny Asset Management held 70,748 shares of Karyopharm Therapeutics worth $394K as of Q1 2026.
  • Karyopharm Therapeutics was a new Balyasny Asset Management position in Q1 2026.
  • Karyopharm Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2459 holding.
  • Balyasny Asset Management first reported a position in Karyopharm Therapeutics in Q3 2014 and has held it in 16 quarters since.
  • Balyasny Asset Management's Karyopharm Therapeutics position peaked at $5.61M in Q4 2020.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.